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Nanostructured drug delivery systems are based on biocompatible and biodegradable components. Com-
position, size and membrane surface properties are characteristics that may inﬂuence cell viability in
cytotoxicity assays. In this work, four nanostructured systems commonly used for drug delivery were
prepared and cytotoxicity was evaluated on human lymphocytes and Balb/c 3T3 ﬁbroblasts. The hemo-
lytic potential was also investigated. Polymeric nanocapsules (NC) and nanospheres (NS), nanostructured
lipid carriers (NLC) and liposomes were prepared and characterized for size, distribution, zeta potential
and number per volume of the colloidal dispersion. Cell viability was evaluated, 24 and 48 h, by MTT and
neutral red assays (NR). Cells were incubated with each particle in eight different dilutions varying from
2.1  104 to 2.1  1011 particles/mL. Diameter of nanoparticles was between 130 and 200 nm, all samples
exhibited narrow size distribution (polydispersity index below 0.1) and zeta potential varied from6.8 to
19.5 mV. NC, NS and NLC reduced cell viability in a dilution dependent manner. For these nanoparticles,
the higher number of particles induced cell death for both cell types. Liposomes did not cause loss of cell
viability even at the highest number of particles. Results suggest that, depending on the kind of nanopar-
ticle, the number of particles in the dispersion can negatively inﬂuence cell viability in pre-clinical drug
development.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Nanoparticles engineered from a variety of organic and inor-
ganic materials nanostructured systems currently applied in vari-
ous ﬁelds, including drug and gene delivery, biosensors, cancer
treatment, diagnostic tools and drug delivery (Kong et al., 2011).
The understanding of the biophysicochemical interfaces
between engineered nanostructured materials and biological sys-
tems is crucial for the design of more advanced biocompatible
and efﬁcient nanodevices addressed for biological applications
(Nel et al., 2009; Shang et al., 2014). Moreover, understanding
the biophysicochemical interactions is very important from the
perspective of safety and pre-clinical development of nanotechnol-
ogy based systems for drug development and delivery.The interactions between nanoparticles and biological systems
including cells, tissues and organisms, is a dynamic process inﬂu-
enced by the properties of the nanosystem, such as, size, surface
of area, shape/angle of curvature, porosity/surface crystallinity,
hydrophobicity/hydrophilicity, chemical functionality, surface
charge, and composition. On the other hand, the nano-biointerfac-
es also inﬂuenced by the composition of the biological systems
(proteins, membranes, phospholipids, organelles, endocytic vesi-
cles, DNA and biological ﬂuids) (Verma and Stellacci, 2010).
Different types of nanostructured systems designed for drug
delivery have been extensively investigated over the past decades.
These include polymeric nanocapsules (NC) and nanospheres (NS),
nanostructured lipid carriers (NLC) and liposomes. Thousands of
papers have been published addressing performance evaluation
of nanoparticulated drug delivery systems in comparison to the
non-nanostructured drug. Most of these studies use cytotoxicity
assays as the main tool for measuring and establishing the interac-
tion of the nanoparticle with a biological system (Afshari et al.,
2014; Cordewener et al., 2000; Kong et al., 2011).
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main purpose of the experiment, in preliminary investigation of
the toxicity of a nanomaterial (Hillegass et al., 2010). Although sev-
eral studies regarding cytotoxicity of nanomaterials are available
in the literature, the vast majority is related to nonbiodegradable
nanoparticles (Love et al., 2012; O’Reilly et al., 2014; Singh and
Ramarao, 2012). However, most nanostructured drug delivery sys-
tems are based on biocompatible and biodegradable components.
In order to obtain reliable data from cytotoxicity studies, carefully
designed experiments must take into consideration not only the
properties of the nanosystem, but also additional critical issues
that may impact its in vitro behavior, such as the concentration
of nanoparticle components, the population of the nanoparticles
and structure/type of the nanoparticle (Elsaesser and Howard,
2012; Jones and Grainger, 2009). All these parameters can interfere
with cellular membrane stability leading to cytotoxicity by pro-
moting an imbalance between intra and extracellular ions, proteins
and other vital molecules required to maintain normal cellular
functions and properties (Love et al., 2012). Limitations of the tech-
niques currently available and the complexity involved in assess-
ing the toxicity of nanoparticles have also been reported (Arora
et al., 2012; Jones and Grainger, 2009; Monteiro-Riviere et al.,
2009; Vorup-Jensen and Peer, 2012).
In this work, four different blank nanostructured systems (NC,
NS, NLC and liposomes) commonly designed for drug delivery were
prepared, characterized for their main parameters (size, size distri-
bution, zeta potential and population number) and their cytotoxic-
ity was evaluated on two distinct cell types: human lymphocytes
and Balb/c 3T3 ﬁbroblasts. The ability of these particles in inducing
hemolysis was also investigated.
2. Material and methods
2.1. Preparation of nanoparticles
Polymeric nanoparticles were prepared by the nanoprecipita-
tion method (Mendes et al., 2014; Mora-Huertas et al., 2012). For
the preparation of polymeric nanospheres (NS), the organic phase
was composed of poly-e-caprolactone (PCL) and sorbitan monoste-
arate dissolved in acetone. For the nanocapsules (NC) capryc/
caprylic triglycerid was also added to the organic solution. The
aqueous solution was prepared with polysorbate 80 at 0.1%(w/v).
The organic solution was poured into the aqueous solution under
magnetic stirring, which was maintained for 30 min. The organic
solvent was removed under reduced pressure in a rotary evapora-
tor (RV 10, Ika, Germany).
Nanostructured lipid carriers (NLC) were obtained by high pres-
sure homogenization under heat (Kasongo et al., 2012; Souza et al.,
2011). The lipid phase was composed of glyceril monostearate,
oleic acid and sorbitan monostearate as surfactant. The lipid mix-
ture was heated at 10 C above the melting point of the solid lipid
and then added to the aqueous phase, containing poloxamer 188
(2.5%). After 1 min in an Ultra-turrax T25 digital (Ika, Germany)
for at 8000 rpm a pre-emulsion with a volume of 200 mL was
formed. The pre-emulsion was submitted to 6 cycles of homogeni-
zation at 500 bar in a Panda 2K (GEA Niro Soavi, Italy) to reduce
particles size and cooled at room temperature to form the NLC.
Liposomes were prepared by the hydration of the thin lipid ﬁlm
method, followed by extrusion (Gaeti et al., 2015; Olson et al.,
1979). Soy phosphatidylcholine was dissolved in chloroform and
after the solvent removal by rotary evaporation a thin lipid ﬁlm
was formed and the ﬂask was kept under vacuum (440/2D, Nova
Ética, Brazil) for at least one hour to remove residual organic sol-
vent. The thin-ﬁlm was hydrated with ultrapure water for 1 h, fol-
lowed by 10 cycles of extrusion (Lipex Extruder, Northern Lipids)
through a 200 nm polycarbonate membrane.2.2. Nanoparticles characterization
Nanoparticles were characterized by zeta potential (f-poten-
tial), pH, particle concentration, polydispersity index (PdI) and size
distribution, which was determined by two methods: dynamic
light scattering (DLS) and nanoparticle tracking analysis (NTA).
PdI and mean size were evaluated by DLS in a Zetasizer Nano-S
(Malvern Instruments, United Kingdom), which presents the mean
intensity scattered by particles in Brownian motion. NTA was
accomplished in a NanoSight NS500 (Amesbury, United Kingdom)
and was used to evaluate particle size and concentration in the
samples. Analysis of pH was done directly in a digital pHmeter
Orion 350 PerpHect (Thermo Scientiﬁc, USA) and zeta potential
was evaluated in a ZetaPlus (Brookhaven Instruments Corporation,
USA). All samples were taken directly from their original aqueous
dispersion and, except for pH measurements, diluted (10%) with
ultrapure water for analysis. NTA measurements were performed
in triplicate for each of the 5 batches characterized in the experi-
ment and all results are expressed by the means ± standard devia-
tion (SD) (n = 5).
2.3. Cytotoxicity assays
Primary culture of human lymphocytes was obtained by veni-
puncture from healthy male donors. Equal amounts of peripheral
blood and RPMI 1640 medium were mixed and layered over Hist-
opaque – 1077 density gradient separation solution (1.077 g/ml),
which were then centrifuged for 20 min at 2000 rpm and room
temperature. The mononuclear cell layer (MCL) was removed,
washed and resuspended in RPMI 160 medium, with 10% fetal
bovine serum (FBS), antibiotics (penicillin 100 IU/mL; streptomy-
cin 100 lg/mL) and 10 lg/ml of phytohemagglutinin. The cells
were cultured for 72 h and after that, 90 lL of the cell suspension
(1  106 cell/ml) was cultured in 96-well microtiter plates, with
and without each of the four types of blank nanocarriers (10 lL)
(NS, NC, Liposomes and NLC) for 24 h, in different concentrations
(2.1  104, 2.1  105, 2.1  106, 2.1  107, 2.1  108, 2.1  109,
2.1  1010, 2.1  1011 particles/mL). Nanoparticle suspensions
were ﬁltered through 0.22 lm Millipore PVDF ﬁlters in order to
ensure sterility prior to cell culture assays.
Assessment of the cytotoxicity on human lymphocytes was per-
formed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide (MTT) reduction assay, adapted from Mosmann
(1983). After 24 h of incubation 10 lL of 3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyltetrazolium bromide (MTT) solution (5 mg/mL)
was added to each well and incubated for 4 h in the same condi-
tions described above. Supernatants were removed and 100 lL of
DMSO were added to each well to solubilize the formazan crystals.
The absorbance was measured on a microplate reader at 570 nm in
a Stat Fax 2100 Microplate Reader (Awareness Tecnologies, USA).
Balb/c 3T3 ﬁbroblasts were cultured as a monolayer in sterile
culture ﬂasks containing DMEM supplemented with 10% FBS. Cells
were daily examined by contrast microscope. They were removed
from the culture ﬂasks using trypsinization (trypsin/EDTA solu-
tion; 0.025%:0.02%) when they reached between 50% and 80% con-
ﬂuence. A cell suspension containing 3  104 cells/mL was
prepared in DMEM supplemented with 10% FBS and 96-well
microtiter plates were seeded and incubated for 24 h for a mono-
layer with less than 50% conﬂuence. After that period, cells were
exposed to eight different concentrations of freshly prepared and
diluted nanoparticles (2.1  104, 2.1  105, 2.1  106, 2.1  107,
2.1  108, 2.1  109, 2.1  1010, 2.1  1011 particles/mL) and incu-
bated for 48 h. Neutral red (NR) assay was performed according to
the standard protocol of Borenfreund and Puerner (1985) modiﬁed
by NICEATM (ICCVAM, 2006). After 48 h of exposure, the cells were
washed and NR medium was added to all wells and incubated for
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3 h, the NR medium was removed, the cells rinsed and NR desorb
(50 EtOH: 1 acetic acid: 49 water) solution was added to all wells.
Optical density (OD) was read at 550 nm in a microtiter plate
reader.
2.4. Hemolysis
Hemolytic potential of all nanoparticles was assessed to evalu-
ate their compatibility. Hemolysis assay was performed using 96-
well plates as previously described (Santos Júnior et al., 2010).
Brieﬂy, human erythrocytes were separated from serum and
washed three times with saline solution containing 0.85% sodium
chloride and 10 mM calcium chloride. Erythrocytes were collected
after centrifugation at 1500 rpm for 5 min and a stock suspension
of 2% (v/v) was prepared diluting themwith the saline solution. Dif-
ferent concentrations of each nanoparticle were analyzed, ranging
from 2  104 to 2  1011 particles/mL. A blank of all concentrations
of nanoparticles was included in the plate to null any color/turbid-
ity interference. A negative control containing only saline solution
and a positive control, containing saline solution and 0.02% Triton
X-100were also included. Except for the blanks, everywell received
the stock solution of erythrocytes. The plate was incubated for two
hours under agitation and centrifuged at 1500 rpm for 10 min. The
supernatant was transferred to another plate and % hemolysis was
measured in spectrophotometer at 450 nm.
2.5. Nanoparticle–cell interactions
In order to investigate the interaction of nanoparticles with
lymphocytes by ﬂow cytometry, nanoparticles were ﬂuorescent-
labeled by the addition of 2% of Egg Liss Rhod PE (L-a-Phosphati-
dylethanolamine-N-(lissaminerhodamine B sulfonyl)) in relation
to the main structural components of each nanoparticle. Peripheral
human blood was obtained by venipuncture from healthy adult
donors, diluted with an equal volume of RPMI 1640 medium, then
layered over Ficoll-Hypaque density gradient separation solution
(1.077 g/ml), and centrifuged at 400g for 20 min at room tempera-
ture. The mononuclear cell layer was removed, washed twice in
RPMI 1640 medium and resuspended in RPMI 1640 medium sup-
plemented with 2 mM glutamine (Sigma Chemical Co.), antibiotics
and 10% FCS then the cells were cultured with 10 lg/mL of phyto-
hemagglutinin. Lymphocytes were incubated with 2.1  109 nano-
particles for up to 6 h. After incubation, as described above, the
lymphocytes were incubated and the analysis (10.000 events were
collected per sample) was performed with a FACS Canto II ﬂow
cytometer (Becton Dickinson, California, USA) using the FACS Diva
software. In addition, the lymphocytes were directly observed in a
Leica DM4000 ﬂuorescence microscope (Wetzlar, Germany).
2.6. Statistical analysis
The evaluation of cytotoxicity was carried out by three separate
experiments. The results were transformed in to percentages of the
control. Results are expressed as the mean ± SD of ﬁve replicates of
three independent experiments. For comparison of mean values
between groups. Analysis of Variance test (ANOVA) and Tukey’s
Multiple Comparison test were used. Statistical signiﬁcance was
considered when p < 0.05.
3. Results and discussions
3.1. Nanoparticles characterization and cell interactions
Mean diameter of the nanostructured drug delivery systems
ranged from 136 to 214 nm, with a narrow size distribution ascan be observed in Fig. 1. Surface area was determined as a func-
tion of the diameter, assuming that nanoparticles were spherical
in shape (Mendes et al., 2014; Oliveira et al., 2012). All nanoparti-
cle formulations exhibited a negative residual surface charge. f-
potential values were lower for liposomes (due to their phospho-
lipid composition) and slightly higher for NS, NC and NLC.
Nanoparticle induced cytotoxicity has been recognized as a
function of the physical-chemical properties of the nanoparticle,
such as size, size distribution, shape and surface chemistry
(Frohlich, 2012; Love et al., 2012; Verma and Stellacci, 2010). How-
ever, little or no attention has been given to the population of the
nanoparticles when conducting in vitro cytotoxicity experiments.
In this work, all nanoparticles evaluated were spherical in shape
and with average diameters between approximately 100 and
200 nm. Components of all nanoparticles formulations are
included in the FDA inactive ingredients database under the classi-
ﬁcation of GRAS (‘‘GRAS’’ is an acronym for Generally Recognized
As Safe) and in equivalent amounts. Most cytotoxicity studies
involving nanostructured drug delivery systems are focused on
the bioactivity of the drug compound (Afshari et al., 2014;
Hashem et al., 2014; Nogueira et al., 2014). However, cytotoxicity
has been observed even for blank nanoparticles during the design
of in vitro experiments using different cell lines (Mendes et al.,
2014; Souza et al., 2011; Stecanella et al., 2013).
Determining the number of nanoparticles in a colloidal disper-
sion was made possible by new methods such as NTA. This tech-
nique allows visualization of particles by the light scattered when
illuminated by a laser light and calculates particle size on a parti-
cle-by-particle basis. A digital camera captures videos of the light
scattered by the particles and their motion is tracked from frame
to frame and relate the movement to a sphere equivalent hydrody-
namic radius, which also counts the number of nanoparticles in the
dispersion. The nanoparticle count (in number of nanoparticles/mL)
for each recently prepared formulation is shown in Fig. 1.
Incubating 3T3 cells and lymphocytes with similar concentra-
tions (by number/mL) of liposomes, polymeric nanospheres and
nanocapsules and NLC indicated that, for certain types of particles,
such as soy phosphatidylcholine liposomes, even at the highest
population density, no cytotoxicity signals are observed. However,
a high population of blank NC, NS and CLN were able to induce
cytotoxicity.
Although each nanoparticle formulation exhibited slightly dif-
ferent values of pH, the ﬁnal pH of the incubation media following
the addition of the NP dispersions to the cell culture media, was
maintained between 7.2 and 7.4. Furthermore, size and size distri-
bution of the nanoparticles did not change following addition to
the cell culture media.
The different types of nanoparticles (NS, NS, Liposomes, NLC)
prepared with ﬂuorescent phospholipids as a structural compo-
nent were incubated with lymphocytes for three to six hours as
represented in Fig. 2. Analysis of cells by ﬂow cytometry shows
the increase of ﬂuorescence in relation to the time of incubation
which represents the interactions of nanoparticles with cells. As
shown in Fig. 5A, incubation of NS, NC or liposomes with lympho-
cytes resulted in increasing cellular internalization of nanoparti-
cles, reaching 21%, 22% and 30% respectively, after 6 h. The
higher nanoparticle–cell interaction was observed for NLC, since
the increase in ﬂuorescent cells reached 66% in 6 h. Photomicro-
graphs of lymphocytes after 6 h of incubation with nanoparticles
indicate a stronger NLC nanoparticle–cell interaction due to the
higher number of ﬂuorescence positive cells.
3.2. Cytotoxicity assays
In the present study the cytotoxicity of four types of blank nano-
carriers (NS, NC, Liposomes and NLC), in different concentrations,
Nanoparticle Particle size /Cumulants fit
Particle size /
Relative intensity
NS
NC
Liposome
NLC
Nanoparticle Size [d.nm] PdI Initial particle count [NP/ml]
Surface Area
[nm2/particle] pH ζ-Potential
NS 136.00 ± 6.05 0,064 ± 0,017 (6,22 ± 0,91)×1012 58,105 ± 2,324 6.23 ± 0.26 (-) 19.38 ± 4.36
NC 214.00 ± 16.09 0,118± 0,0459 (4,77 ± 2,30)×10
12 143,872 ± 10,790 5.78 ± 0.94 (-) 15.02 ± 4.99
Liposome 166.17 ± 7.35 0,150 ± 0,069 (6,98 ± 1,80)×1013 86,569 ± 3,809 4.74 ± 0.06 (-) 6.86 ± 4.01
NLC 195.07 ± 10.76 0,180 ± 0,062 (4,96 ± 1,95) ×10
12 118,236 ± 5,911 7.24 ± 0.50 (-) 19.48 ± 2.77
Fig. 1. Size, size distribution, surface area, pH and zeta potential of nanospheres (NS), nanocapsules (NC), liposomes and nanostructured lipid carriers (NLC). Particle size and
size distribution (PdI) were determined by dynamic light scattering. Particle count was obtained by nanoparticle tracking analysis. Zeta-potential was determined by
electrophoretic mobility followed by dynamic light scattering. Surface area was estimated for spherical particles. Data represent the mean ± SD of ﬁve independent
experiments.
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Fig. 2. Nanoparticle-lymphocyte interactions after 3, 4 and 6 h of incubation. (A) Hystograms of ﬂow cytometer analysis of nanospheres (NS), nanocapsules (NC), liposomes
and nanostructured lipid carriers (NLC). (B) Photomicrographs of lymphocytes after 6 h of incubation with nanoparticles. (C) Number (%) of cells positive for the ﬂuorescent
marker from nanoparticles as a function of incubation time.
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dispersion (2.1  104, 2.1  105, 2.1  106, 2.1  107, 2.1  108,
2.1  109, 2.1  1010, 2.1  1011 particles/mL), was investigated
using human lymphocytes by the MTT reduction assay. Potential
interferences of the nanoparticles with the readings of the cytotox-
icity assay were ruled out by a preliminary assay, in which each
nanoparticle dispersion was incubated with theMTT solution. After
incubation, no changes were observed in the solution color indicat-
ing that the particles did not interact with the dye.
As represented in Fig. 3, following the incubation period of 24 h
with the liposomal dispersion, in all concentrations studied, cell
viability was not changed. However, when cells were exposed to
NS or NC in the higher concentration (2.1  1011 nanoparticles/
mL) reductions of 17% and 16%, respectively, on the cell viability,in comparison with non-exposed cells, were observed. Moreover,
the incubation of lymphocytes with NLC at concentrations of
2.1  1010 and 2.1  1011 nanoparticles/mL lead to a marked
reduction of cell viability, reaching 55% of that of control cells.
When the blank nanocarriers (NS, NC, Liposomes and NLC), in
different concentrations (number of nanoparticles/mL of the colloi-
dal dispersion) were incubated with Balb/c 3T3-A31 and evaluated
by the NRU cytotoxicity assay, following incubation for 48 h, sim-
ilar results were observed for liposomes, with no recorded cytotox-
icity (Fig. 4). The NLC resulted the highest cytotoxic effects, in
relation the other particles, reaching a reduction in the viability
of 58% at the concentration of 2.1  1010 nanoparticles/mL. When
cells were exposed to either NLC, NS and NC at the concentration
of 2.1  1011 nanoparticles/mL, cell viability was reduced to
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Fig. 3. Effect of nanoparticles on human lymphocyte cell viability. Cells were
exposed to different concentrations (number/mL) of nanoparticles for 24 h. At the
end of incubation period MTT assay was performed to assess cell viability. Control
cells were cultured in nanoparticle-free media. Cell viability was calculated as a
percentage of the control group. The data are expressed as mean ± SD of three
independent experiments. P < 0.05⁄ in relation to NC. P < 0.05# in relation to
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individual components of each nanosystem did not interfere with
cell viability under the same conditions (data not shown).
Ridolﬁ et al. (2011) studied the cytototoxic potential of solid
lipid nanoparticles (SLN) prepared with three different lipids
(cetylpalmitate, myristylmyristate and cetyl ester), by MTT assays,
against Balb/c 3T3 ﬁbroblasts or human HaCaT keratinocytes. Even
though the authors were not able to determine IC50 for the nano-
particles formulations, the results demonstrated that the viability
of exposed cells was signiﬁcantly reduced for SLN prepared with
the highest concentration of lipids tested (500 lg/mL).
A recent review article by Doktorovova et al. (2014) presents
both supporting and conﬂicting data on the toxicity of SLN and
NLC, pointing that neither size or composition plays a pivotal role
in the toxicity exhibited by these nanoparticles, although type and
amount of surfactant in the formulation might inﬂuence their cyto-
toxicity. Our results are in agreement with these data, in addition
to providing insights on the inﬂuence of the number of nanoparti-
cles in the dispersion on the cytotoxicity of the formulations.
Polymeric nanoparticles and solid lipid nanoparticles are not
yet widely available for therapeutic uses as intravenous formula-
tions. The number of nanoparticles in any given formulation will
be a function of their structural material, as well as the encapsu-
lated drug and encapsulation efﬁciency. On the other hand, lipo-
somes have been available for therapeutic uses for approximately
two decades (Chang and Yeh, 2012). In this study, liposomes did25
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Fig. 4. Effect of nanoparticles on BALB/c 3T3 cell viability. Cells were exposed to
different concentrations (number/mL) of nanoparticles for 48 h. At the end of
incubation period Neutral Red assay was performed to assess cell viability. Control
cells were cultured in nanoparticle-free media. Cell viability was calculated as a
percentage of the control group. The data are expressed as mean ± SD of three
independent experiments. P < 0.05⁄ in relation to liposome.not exhibit any cytotoxic behavior, even at the highest number
of particles per volume.
3.3. Hemolysis
Fig. 5 shows hemolysis from RBCs exposed to blank nanocarri-
ers (NS, NC, Liposomes and NLC), in different concentrations (num-
ber of nanoparticles/mL of the colloidal dispersion). Hemolytic
activity was only observed with NLC, while other blank nanoparti-
cles showed less than 2% of hemolysis. NLC at 2.1  1010 and
2.1  1011 induced 50% and 93.5% of hemolysis, respectively. It
has been noted that slight RBC alterations, such as deformability
and aggregation, could result in circulatory damages to the macro
and microvasculature (Kim and Shin, 2014). The hemolysis process
observed in this study indicates a direct interaction between NLC
and the RBC membrane, associated with the high population of
the nanoparticles.
4. Conclusions
In this study, cytotoxicity of biodegradable nanocarriers
designed for drug delivery was investigated. Nanoparticles were
prepared to exhibit similar size, size distribution, shape, surface
charge and main composition, however showed different cellular
interaction behaviors. Changes in the population density of the
nanoparticles (number/mL) resulted in cytotoxicity responses par-
ticularly for NLCs. Results suggest that, depending on the kind of
nanoparticle, the number of particles in the dispersion can nega-
tively inﬂuence cell viability in pre-clinical drug development
and delivery studies. Additional studies are required to establish
parameters for investigating cytotoxicity of drug delivery nanopar-
ticles in which the number of nanoparticles in dispersion does not
induce cell damage.
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